21 CFR Part 211
Every DSRV article whose Regulatory Snapshot cites 21 CFR Part 211: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR Part 211?
- 3 DSRV articles cite 21 CFR Part 211. Enforcement cases behind them: FDA CGMP warning letters posted June 2, 2026: Revlon Group Holdings LLC, Umendra Life Sciences Private Limited, Shantou Qiwei Industry Co. Ltd., Laboratorios Dr. Collado S.A., Zydus Lifesciences Limited (component control/talc-asbestos cluster). Macau-Union Pharmaceutical Limited WL 724506, issued May 29, 2026 (release testing/microbiological/sub-potency/import alert); WL 724506 (Macau-Union Pharmaceutical Limited, May 29 2026); WL 722596 (Revlon Group Holdings LLC, June 2 2026); plus six additional CDER CGMP letters posted June 9 2026; NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers. Inspection exposure across them: 3 high.
- What does DSRV recommend for 21 CFR Part 211?
- From the newest article (COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.): FDA enforcement is drawing a bright line between documented testing activity and defensible quality evidence. COAs document supplier claims; they do not document manufacturer verification. Your incoming testing program must stand independently. DSRV is decision support, not legal advice; verify against the official source each article names.
- 5 min readHigh exposure
COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.
Five CGMP warning letters in one posting cycle. Five manufacturers. The common thread: treating a supplier certificate of analysis as the endpoint of component verification instead of one data point in it. FDA's June 2026 cluster makes the distinction explicit.
- Case
- FDA CGMP warning letters posted June 2, 2026: Revlon Group Holdings LLC, Umendra Life Sciences Private Limited, Shantou Qiwei Industry Co. Ltd., Laboratorios Dr. Collado S.A., Zydus Lifesciences Limited (component control/talc-asbestos cluster). Macau-Union Pharmaceutical Limited WL 724506, issued May 29, 2026 (release testing/microbiological/sub-potency/import alert).
- DSRV take
- FDA enforcement is drawing a bright line between documented testing activity and defensible quality evidence. COAs document supplier claims; they do not document manufacturer verification. Your incoming testing program must stand independently.
- 6 min readHigh exposure
Eight Warning Letters, One Day: FDA's June 9 Evidence Sweep
FDA posted eight CGMP warning letters in a single June 9 update. Macau-Union and Revlon anchor a multi-domain enforcement case that spans release testing, stability support, and component qualification simultaneously, and the pattern applies well beyond those two firms.
- Case
- WL 724506 (Macau-Union Pharmaceutical Limited, May 29 2026); WL 722596 (Revlon Group Holdings LLC, June 2 2026); plus six additional CDER CGMP letters posted June 9 2026.
- DSRV take
- FDA enforcement maps where quality systems accumulate evidence gaps at specific boundaries. This cluster shows those gaps are not single-domain: release testing, stability, and component qualification can each fail while procedures remain in place.
- 6 min readHigh exposurecited as a tag
108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.
NAFDAC's 5+5 Policy approved 108 new pharmaceutical manufacturing sites by early 2026. Sixty-three of them are first-time manufacturers with no inspection history, entering a supply chain where WHO prequalification assessments will test what local approval did not.
- Case
- NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers.
- DSRV take
- NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR Part 211. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.